Alumis (ALMS) is faced with a narrowing path forward amid a promising profile, Oppenheimer said in a report Sunday.
The note said envudeucitinib showed "rapid, robust, and durable" efficacy in psoriasis via the ONWARD clinical program.
"However, ALMS' need for a partner to compete commercially with JNJ's Icotyde and TAK's zasocitinib made the story challenging for investors, with no clear path forward on its own," it said. JNJ refers to Johnson & Johnson, and TAK to Takeda.
The note also said opportunity in systemic lupus erythematosus
narrows following positive competitor results.
Oppenheimer kept its outperform rating while lowering its price target to $28 from $37 after reducing penetration assumptions.
Price: 5.05, Change: -0.55, Percent Change: -9.82
Comments